Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs

DR Tompa, A Immanuel, S Srikanth… - International journal of …, 2021 - Elsevier
The infectious microscopic viruses invade living cells to reproduce themselves, and causes
chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to …

Approved antiviral drugs over the past 50 years

E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

[HTML][HTML] Systematic review of the incidence and prevalence of genital warts

H Patel, M Wagner, P Singhal, S Kothari - BMC infectious diseases, 2013 - Springer
Abstract Background Anogenital warts (AGWs) are a common, highly infectious disease
caused by the human papillomavirus (HPV), whose high recurrence rates contribute to direct …

[HTML][HTML] Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Future II Study Group - New England Journal of Medicine, 2007 - Mass Medical Soc
Background Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause
approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate …

Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer

C Chelimo, TA Wouldes, LD Cameron, JM Elwood - Journal of Infection, 2013 - Elsevier
Genital HPV infection is associated with development of cervical cancer, cervical neoplasia,
anogenital warts, and other anogenital cancers. A number of reviews have primarily …

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine

SM Garland, M Steben, HL Sings… - The Journal of …, 2009 - academic.oup.com
Background The placebo arm of human papillomavirus (HPV) vaccine trials helps define the
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …

[HTML][HTML] Genital warts: a comprehensive review

VR Yanofsky, RV Patel… - The Journal of clinical and …, 2012 - ncbi.nlm.nih.gov
External genital warts, also known as condylomata acuminata, are extremely common, with
between 500,000 to one million new cases diagnosed each year in the United States alone …

[HTML][HTML] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and …

Future I/II Study Group - The BMJ, 2010 - ncbi.nlm.nih.gov
Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV)
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …

EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …